Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

FDA reviewer backs approval of TMC’s cangrelor

Claims it offers a small benefit over Sanofi’s Plavix

- PMLiVE

AZ’s Onglyza may increase mortality, says FDA

Kombiglyze also under scrutiny

- PMLiVE

Going the distance

Sanofi’s Pascale Witz on driving through change

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Merck adds another immuno-oncology tie-up

Firm to test Keytruda with Syndax’s entinostat in melanoma and NSCLC

- PMLiVE

Novartis cancer pill makes it onto UK early access list

Joins Merck’s melanoma drug Keytruda for the MHRA’s accelerated review programme 

- PMLiVE

Novo Nordisk will refile rejected diabetes duo in US

Danish firm hopes it will be second time lucky with key treatment

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

R&D productivity takes off

Approvals of NMEs reach heights last seen in the mid-1990s

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links